'Policy Forces' Retarding Pharmacogenomic-Backed Off-Label Rx Use | GenomeWeb
NEW YORK (GenomeWeb News) — “Policy forces” inside the US government are preventing genomic technologies from helping physicians make off-label prescribing decisions, according to a prominent US Food and Drug Administration official.
 
“Medicine is becoming more personalized as tools like genomics make it possible to tailor treatments on an individual basis,” Scott Gottlieb, deputy commissioner for medical and scientific affairs, said in a speech at Windhover's FDA/CMS Summit in Washington, DC, earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.